Why Did INDP Stock Gain 12% Today?

The investment includes 300,000 Series AA preferred shares and 700,000 Series AAA preferred shares.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.(Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

Shivani Kumaresan·Stocktwits

Published Dec 29, 2025 | 7:33 AM EST

Add us on

Indaptus Therapeutics Inc. (INDP) announced on Monday that it has secured a $6 million investment through the sale of non-voting convertible preferred stock to investor David E. Lazar.

Following the announcement, Indaptus’ stock traded over 12% higher. However, on Stocktwits, retail sentiment around the stock changed to ‘bearish’ from ‘extremely bearish’ territory the previous day amid ‘extremely low’ message volume levels.

Transaction Details

The investment, finalized on December 23, includes 300,000 Series AA preferred shares and 700,000 Series AAA preferred shares. Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150, pending stockholder approval expected in the first-quarter (Q1) 2026.

Get updates to this developing story directly on Stocktwits.

Add us on

Read about our editorial guidelines and ethics policy

Premarket Equities